Modern multiple sclerosis treatment - what is approved, what is on the horizon. Export

@article{citeulike:5015648, abstract = {In the mid-1990s, the implementation of the immunomodulatory drugs interferon-beta and glatiramer acetate offered the first evidence-based treatment option for multiple sclerosis (MS). These new drugs were beneficial in a huge number of MS patients worldwide, leading to a delay in disease-related disability. Moreover, MS was suddenly the focus not only of patients and their physicians but also of pharmaceutical companies, with a tremendous increase in interest by scientists. As a result of these efforts the first monoclonal antibody treatment has recently been implemented in MS. It will presumably be followed by several other more specific, more effective and more comfortable therapies within the next few years. Here, we will show the current MS treatment options as well as recent progress in the field, and we will introduce the potential new treatment options for future MS therapy.}, author = {Pilz, G. and Wipfler, P. and Ladurner, G. and Kraus, J.}, citeulike-article-id = {5015648}, citeulike-linkout-0 = {http://dx.doi.org/10.1016/j.drudis.2008.08.003}, citeulike-linkout-1 = {http://view.ncbi.nlm.nih.gov/pubmed/18775508}, citeulike-linkout-2 = {http://www.hubmed.org/display.cgi?uids=18775508}, doi = {10.1016/j.drudis.2008.08.003}, issn = {1359-6446}, journal = {Drug discovery today}, keywords = {master, ms}, month = {December}, number = {23-24}, pages = {1013--1025}, posted-at = {2009-06-29 22:12:21}, priority = {2}, title = {Modern multiple sclerosis treatment - what is approved, what is on the horizon.}, url = {http://dx.doi.org/10.1016/j.drudis.2008.08.003}, volume = {13}, year = {2008} }

TY - JOUR ID - citeulike:5015648 L3 - citeulike-article-id:5015648 N2 - In the mid-1990s, the implementation of the immunomodulatory drugs interferon-beta and glatiramer acetate offered the first evidence-based treatment option for multiple sclerosis (MS). These new drugs were beneficial in a huge number of MS patients worldwide, leading to a delay in disease-related disability. Moreover, MS was suddenly the focus not only of patients and their physicians but also of pharmaceutical companies, with a tremendous increase in interest by scientists. As a result of these efforts the first monoclonal antibody treatment has recently been implemented in MS. It will presumably be followed by several other more specific, more effective and more comfortable therapies within the next few years. Here, we will show the current MS treatment options as well as recent progress in the field, and we will introduce the potential new treatment options for future MS therapy. IS - 23-24 JF - Drug discovery today SN - 1359-6446 EP - 1025 TI - Modern multiple sclerosis treatment - what is approved, what is on the horizon. VL - 13 SP - 1013 KW - master KW - ms AU - Pilz, G AU - Wipfler, P AU - Ladurner, G AU - Kraus, J PY - 2008/12// UR - http://dx.doi.org/10.1016/j.drudis.2008.08.003 ER -